[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.48.224. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 888
Citations 0
Correction
July 2015

Error in Table Text

JAMA Oncol. 2015;1(4):544. doi:10.1001/jamaoncol.2015.1424

In the Research Letter titled “Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs” published online in the April 2, 2015, issue of JAMA Oncology (doi:10.1001/jamaoncol.2015.0373), an incorrect indication was listed for ibrutinib in the Table. The correct indication is mantle cell lymphoma. This article was corrected online.

×